J Biol Chem, Vol. 274, Issue 53, 38083-38090, December 31, 1999
MAPK Mediates RAS-induced Chromosome Instability*
Harold I.
Saavedra
,
Kenji
Fukasawa,
Christopher W.
Conn, and
Peter J.
Stambrook§¶
From the § Department of Cell Biology, Neurobiology and
Anatomy, University of Cincinnati College of Medicine,
Cincinnati, Ohio 45267-0521
 |
ABSTRACT |
The generation of micronuclei is a reflection of
DNA damage, defective mitosis, and loss of genetic material. The
involvement of the MAPK pathway in mediating v-ras-induced
micronuclei in NIH 3T3 cells was examined by inhibiting MAPK
activation. Conversely, the MAPK pathway was constitutively activated
by infecting cells with a v-mos retrovirus. Micronucleus
formation was inhibited by the MAPK kinase inhibitors PD98059 and
U0126, but not by wortmannin, an inhibitor of the
Ras/phosphatidylinositol 3-kinase pathway. Transduction of cells with
v-mos resulted in an increase in micronucleus formation,
also consistent with the involvement of the MAPK pathway. Staining with
the anti-centromeric CREST antibody revealed that instability induced
by constitutive activation of MAPK is due predominantly to aberrant
mitotic segregation, since most of the micronuclei were CREST-positive,
reflective of lost chromosomes. A significant fraction of the
micronuclei were CREST-negative, reflective of lost acentric chromosome
fragments. Some of the instability observed was due to mitotic events,
consistent with the increased formation of bi-nucleated cells, which
result from perturbations of the mitotic spindle and failure to undergo
cytokinesis. This chromosome instability, therefore, is a consequence
of mitotic aberrations, mediated by the MAPK pathway, including
centrosome amplification and formation of mitotic chromosome bridges.
 |
INTRODUCTION |
The Ras proteins are small (21 kDa) GTP-binding,
membrane-associated proteins (1). They are in their activated state
when bound to GTP, and are inactivated by GTP hydrolysis. This
intrinsic GTPase activity is enhanced by association with
GTPase-activating protein (1). The Ras proteins transduce signals from
ligand-activated tyrosine kinase receptors to downstream effectors (2).
Activating mutations, such as those in EJ Ras, can impair
GTP hydrolysis and lead to constitutively activated Ras that impacts
the cellular phenotype (3). Oncogenic Ras can lead to
cellular transformation (4), presumably by perturbing its signal
transduction pathways.
Among the most thoroughly studied of the Ras-mediated pathways is the
threonine/serine MAP1 kinase
cascade (5-7). One major downstream target of the MAPK pathway is the
AP-1 transcription complex, and the constitutive activation of AP-1
results in altered transcription of AP-1-regulated genes (8). The Ras
signal transduction pathway is complex with multiple intersections and
bifurcations (9-11). Cells utilize the various Ras-mediated signal
transduction pathways to regulate a plethora of phenotypes such as cell
growth (12, 13), the differentiation of certain cells types
(i.e. PC-12) (13, 14), and morphological transformation via
Rac1, RhoA, Cdc42, and c-Jun NH2-terminal kinase kinase
(15-18). Ras also can mediate responses to hypoxia via NF
B (19) and
responses to a variety of environmental stresses via c-Jun
NH2-terminal kinase kinase (20-23), as well as apoptosis
in response to FAS (24, 25), and tumor necrosis factor (26). Ras can
also stimulate the PI3K pathway (27) to induce cellular transformation
and control the actin cytoskeleton (28).
In the absence of p53, a protein that monitors changes in the stability
of the genome (29-31), overexpression of the RAS oncogene leads to
chromosomal instability. In NIH 3T3 cells, selective induction of the
human EJ Ha-ras oncogene expression leads to potentially
deleterious cellular phenotypes such as premature entry of cells into S
phase (32, 33) and increased permissivity for gene amplification (34,
35). Oncogenic Ras also induces the generation of chromosome
aberrations such as dicentric chromosomes, acentric chromosomes, and
double minute chromosomes (33, 36). Chromosome aberrations induced by
oncogenic Ras lead to improper segregation of chromosomes
and the consequent exclusion of chromosomes from daughter nuclei (37,
38). Overexpression of oncogenic ras also produces
chromosome aberrations in rat mammary carcinoma cells (39), in rat
prostatic tumor cells (40), and in a human colon carcinoma cell
line (41). Thus, one of the major consequences of oncogenic
ras in carcinogenesis is destabilization of the karyotype.
Since Ras serves as a focal point for multiple signal transduction
pathways, we have examined whether activation of the Ras/MAPK pathway
is sufficient to induce chromosome instability. To this end, we have
expressed constitutively activated ras, and mos
(a serine threonine kinase known to activate primarily the MAPK
pathway) in NIH3T3 cells, and have used specific inhibitors of MAPKK-1 and -2 to assess the role of the MAPK pathway in inducing chromosome instability. Overexpression of oncogenic ras and
mos resulted in chromosome instability, as measured by a
standard micronucleus assay (42). This chromosome instability is
mediated by activation of the MAPK pathway, and was characterized, in
part, by whole chromosome loss, as well as chromosome fragment loss.
 |
EXPERIMENTAL PROCEDURES |
Retroviral Vectors and Retroviral Infection--
Infectivity of
ecotropic cell lines producing empty Murine leukemia virus
(MuLV), v-ras (MSV-Ha-ras), and v-mos
has been calculated to be between 5 and 10 viral particles per cell
(43). Between 1 and 2 × 105 NIH 3T3 cells were plated
in 6-well plates in Dulbecco's modified Eagle's high glucose medium
containing penicillin/streptomycin and 10% fetal bovine serum.
Infections with MuLV, as with v-mos and
v-ras retroviruses were carried out with 4 µg/ml Polybrene for 4-8 h. For experiments involving the MAPKK inhibitors PD98059 and
U0126, cells were infected with v-ras as described above and the inhibitors were applied at concentrations of 75 µM
for PD98059 and 50, 80, and 100 µM for U0126. Wortmannin
was applied at a concentration of 1 µM. Fresh inhibitor
was applied every 2 days.
Western Blots--
Cellular proteins were isolated by lysing
cells in RIPA solution (150 mM NaCl, 1% Nonidet P-40,
0.5% deoxycholate, 0.1% SDS, 50 mM Tris-HCl, pH 8.0) in
the presence of protease inhibitors (aprotinin, 0.1 µg/ml; leupeptin,
0.5 µg/ml; pepstatin, 1 µg/ml; phenylmethylsulfonyl fluoride, 20 µg/ml;
N
-p-tosyl-L-lysine
chloromethyl ketone, 50 µg/ml; and
L-1-tosylamido-2-phenylethyl chloromethyl ketone, 100 µg/ml) and phosphatase inhibitors (5 mM sodium fluoride
and 0.01 mM sodium orthovanadate) and incubating at 4 °C
for 15 min (44). Protein lysates (50 µg) were denatured in 2% SDS,
10 mM dithiothreitol, 60 mM Tris, pH 6.8, and
0.1% bromphenol blue, and loaded onto a 12% polyacrylamide/SDS gel. The separated proteins were then transferred by electroblot (100 mA,
1 h) onto a PVDF-Plus membrane (Micron Separations Inc.,
Westborough, MA). The blot was blocked in 1 × TBS (0.2 M Tris-Cl, 1.37 M NaCl, pH 7.6), 0.2% Tween
20, 5% nonfat dry milk for 1 h, incubated either with antibody
against Ras (Santa Cruz Laboratories, Santa Cruz, CA), phosphorylated
p42/p44 MAPK, phosphorylated AKT (New England Biolabs, Beverly, MA),
phosphorylated p38, phosphorylated JNK or MAPK-2 (Santa Cruz
Laboratories, Santa Cruz, CA). After washing with 1 × TBS, 0.2%
Tween 20, 5% nonfat dry milk, the membrane was incubated with an
anti-IgG antibody conjugated to horseradish peroxidase (Bio-Rad), and
then washed in 1 × TBS, 0.1% Tween 20. The ECL non-radioactive
detection system (Amersham Pharmacia Biotech) was utilized to detect
the antibody-protein complexes by exposure of the membrane to a Kodak
X-Omat autoradiography film.
Micronucleus Assay--
The micronucleus assay was performed
using a standard procedure (42). Briefly, cells were trypsinized 5-7
days after infection, centrifuged at 1500 rpm for 3 min in a table top
centrifuge, and lysed in 600 µl of solution I (10 mM
NaCl,, 3.4 mM sodium citrate, 0.001% (w/v) RNase A, 0.03%
Nonidet P-40) supplemented with 0.2 µl of 5 mM sytox
(Molecular Probes Inc., Eugene, OR) and incubated at 25 °C for
1 h. This incubation was followed by addition of 600 µl of
solution II (1.4% citric acid, 0.25 M sucrose)
supplemented with 2 µl of propidium iodide (PI) (10 mg/ml).
Micronuclei (particles staining with both sytox and PI with a size
range of 1/100-1/10 the mean size of a G1 nucleus) were
analyzed using a Coulter EPICS XL flow cytometer (Miami, FL) at an
excitation range of 488 nm (argon laser) and a 525 band-pass filter for
sytox and 620 band-pass for PI. Quantitation of micronuclei was based
on 10,000 cells counted. The frequency of micronucleus formation was
confirmed by visual observation of PI-stained nuclei by fluorescence microscopy.
Staining of Kinetochores with CREST Antibody--
Analysis of
micronuclei by immunocytochemistry has been described previously
(45-52). Between 1 × 103 and 1 × 104 cells infected with MuLV, v-ras,
or v-mos were replated 5 days after infection into Falcon
4-well polystyrene chamber slides (Becton Dickinson Labware, Franklin
Lakes, NJ) and cultured for an additional 3 days. Cells were fixed with
3.8% paraformaldehyde, washed with PBS, permeabilized with 0.1%
Triton X-100, 0.025% SDS, for 5 min and blocked with 10% goat serum,
1% bovine serum albumin, 0.01% sodium azide in PBS, for 2 h at
25 °C, and stained with the anti-kinetochore antibody CREST
(Antibodies Inc., Davis, CA) at a 1:10 dilution in blocking solution
for 24 h at 4 °C. After washing, cells were incubated in
anti-human Alexa-488-coupled antibody (Molecular Probes) at a 1:500
dilution in blocking solution for 1-2 h at 25 °C, followed by
washing in 1× PBS and staining with antifade solution (Vectashield,
Vector Laboratories) containing propidium iodide (5 µg/ml). Three to
five optical sections of cells containing micronuclei were analyzed on
a Bio-Rad confocal microscope (Kalman mode). The percentage of CREST
positive cells were then calculated for each experimental condition.
The same slides were utilized to calculate the percentage of
micronuclei, binucleated cells, and fragmented cells in the population.
Cell Cycle Analysis by Flow Cytometry--
Cells
(105) were plated into each well of a 6-well tissue culture
dish and infected with MuLV or v-ras in the
presence or absence of PD98059, U0126, or wortmannin. Cells were
collected and fixed in 70% ethanol at 4 °C, washed in 1 × PBS, resuspended in a solution containing 100 µg of PI, and 1 mg of
RNase A, 10 ml of PBS, and analyzed by flow cytometry (53) using a
Coulter EPICS XL flow cytometer (Miami, FL) at an excitation range of
488 nm (argon laser), and a 620 band-pass filter for PI. The percentage
of cells in G1, S, and G2/M was based on 10,000 cells counted.
Staining of the Mitotic Spindle and Centrosomes--
Cells
(5 × 104) were plated onto gelatinized (0.1% gelatin
in PBS) 2-well plastic culture chambers (Fisher, St. Louis, MO). Cells
were infected with MuLV and v-ras as described
above in the presence or absence of PD98059, U0126, or wortmannin. Five days after infection, cells were stained as follows (54): cells were
rinsed with PHEM (60 mM Pipes, 25 mM Hepes, pH
6.9, 10 mM EGTA, 4 mM MgSO4 fixed
in 4% paraformaldehyde for 15 min, washed in PHEM, and extracted for 5 min at room temperature with PHEM plus 1% CHAPS. Cells were rinsed
with MBST (10 mM MOPS, 150 mM NaCl, 0.005%
Tween 20, pH 7.4) and blocked in 20% normal goat serum in MBST for
2 h. Cells were then incubated for 1 h at room temperature in
MBST containing 5% normal goat serum and rabbit anti-
(1:200
dilution) and mouse anti-
-tubulin (1:200 dilution) antibodies
(Sigma). Cells were washed three times in MBST for 5 min each wash, and
incubated with MBST containing 5% normal goat serum and anti-rabbit
Alexa-488 and anti-mouse Alexa-546 secondary antibodies (Molecular
Probes) for 1 h at room temperature. Cells were washed three times
in MBST at room temperature for 5 min each wash and counterstained with
4',6-diamidino-2-phenylindole (DAPI, Sigma) at 0.5 µg/ml. Cells were
visualized using a standard fluorescence microscopy and a ×100 objective.
 |
RESULTS |
RAS-induced Cellular Transformation Is Dependent upon MAPK
Phosphorylation--
NIH 3T3 cells were infected with either virus
harboring oncogenic ras (MSV-Ha-ras, in
short, v-ras) or MuLV, the parental virus. To
test for expression of Ras, pools of NIH 3T3 cells infected with
MuLV or v-ras were first analyzed by Western
blots using anti-Ras antibody as a probe (Fig.
1). Cells infected with v-ras (Fig. 1, lane 2), but not those infected with control
MuLV (Fig. 1, lane 1), expressed an
increased level of RAS. Equal loading was monitored by using an
antibody against MAPK-2 (Fig. 1).

View larger version (49K):
[in this window]
[in a new window]
|
Fig. 1.
Detection of transgenic Ras expression by
Western blot. NIH 3T3 cells were infected with an ecotropic
MuLV retrovirus (lane 1) or an ecotropic
retrovirus expressing v-ras (lane 2) and proteins
from cell lysates were subjected to polyacrylamide gel electrophoresis
and probed with antibody to RAS and to MAPK-2 to monitor loading.
|
|
Since the MAPK pathway is a major signal transduction pathway activated
by RAS (5-7), we have assessed the extent to which v-ras is
able to induce MAPK activation in the infected cells. Phosphorylation
of MAPK was monitored by Western blots, using an antibody directed
against phosphorylated p42/p44 MAPK. Transduction of exponentially
growing cells with v-ras (Fig.
2A, lane 3) or v-mos (Fig. 2A, lane 2) induced higher MAPK
activation than in cells transduced with MuLV (Fig.
2A, lane 1). Treatment of ras-transduced cells
with the specific MAPKK inhibitors PD98059 and U0126 resulted in
reduction of MAPK phosphorylation (Fig. 2A, lanes 4-6). The inhibitor concentration resulting in 50% inhibition of MAPK activation was 75 µM for PD98059; 50 µM U0126 resulted
in 75% inhibition of MAPK activation. Treatment of
v-ras-infected cells with 80 µM U0126 resulted
in 90% inhibition of MAPK activation, and 100 µM
resulted in total inhibition of MAPK activation (not shown). Transduction with v-ras also resulted in the activation of
the PI3K pathway, as determined by an increase in the phosphorylation of AKT (Fig. 2B, lane 2). Treatment of
v-ras-transduced cells with 1 µM wortmannin
resulted in total inhibition of AKT phosphorylation. Ras did not result
in a detectable activation of the JNK or p38 proteins (data not shown).
Transduction with v-ras or v-mos resulted in a
change in cellular morphology characteristic of transformation (Fig.
3, B and C).
Cellular transformation induced by v-ras was dependent on
phosphorylation of MAPK by MAPKK as indicated by the capacity of the
MAPKK inhibitor U0126 to revert cells to a flat morphology (Fig.
3D). Treatment with wortmannin had no effect on cellular
morphology (not shown).

View larger version (46K):
[in this window]
[in a new window]
|
Fig. 2.
Retroviral infection with v-ras
leads to activation of MAPK, which is inhibited by MAPKK
inhibitors, and to activation of the PI3K pathway, which is inhibited
by wortmannin. Panel A, activation of the MAPK pathway
by v-ras and v-mos. NIH 3T3 cells were infected
with MuLV (lane 1), v-mos (lane
2), or v-ras (lane 3). v-ras plus
75 µM PD98059 (lane 4), v-ras plus
50 µM U0126 (lane 5), or v-ras plus
80 µM U0126 (lane 6). Western blots were done
5 days after infection and probed with antibodies against
phosphorylated MAPK (p-MAPK) or with an antibody against MAPK-2 to
monitor equal loading. Panel B, activation of the PI3K/AKT
pathway by RAS. NIH 3T3 cells were infected with MuLV
(lane 1), or v-ras in the absence (lane
2) or presence of 1 µM wortmannin (lane
3). Lysates were subjected to polyacrylamide gel electophoresis
and probed with antibody against phosphorylated AKT or against MAPK-2
to monitor loading.
|
|

View larger version (168K):
[in this window]
[in a new window]
|
Fig. 3.
Expression of ras and
mos transforms NIH3T3 cells via activation of
MAPK. NIH 3T3 cells were infected with MuLV (A),
v-mos (B), v-ras (C) or
v-ras plus 80 µM U0126 (D). Cells
were photographed using a ×10 objective on a Nikon phase-contrast
microscope.
|
|
The ras and mos Oncogenes Induce Micronuclei Formation--
One
consequence of oncogenic ras expression or mos
expression and the activation of downstream signaling is the induction of chromosome instability (33-37, 43, 55). To confirm that ras and mos induce genomic instability in NIH 3T3
cells, chromosome instability was assessed by the generation of
micronuclei. This measure has been used as a marker of whole chromosome
loss or chromosome fragment loss induced by DNA-damaging agents such as ionizing radiation, or by agents that interfere with the proper functioning of the mitotic spindle and lead to aneuploidy (45-52). Immunocytochemical observation of cells infected with MuLV,
v-ras, or v-mos (Fig.
4) revealed that overexpression of
v-ras (Fig. 4, B and D) and
v-mos (Fig. 4C) induced loss of chromosomes,
revealed by the appearance of micronuclei in the cytoplasm. Analysis of micronucleus formation by flow cytometry (Fig.
5) and independently by
immunocytochemistry (Fig. 6) showed that
overexpression of oncogenic ras and mos induced
the formation of micronuclei. At the high levels of active MAPK induced
by v-ras, the frequency of micronucleus formation rose to
8.6-fold (Figs. 5 and 6), whereas transduction with v-mos
resulted in a 2.1-fold increase in micronucleus formation (data not
shown). Since increases in growth rates can potentially lead to
increases in genomic instability, we calculated doubling times for
cells infected with v-ras and vector controls. In cells
overexpressing v-ras, there was a significant increase in
the doubling time (Table I).

View larger version (41K):
[in this window]
[in a new window]
|
Fig. 4.
Expression of ras and
mos induces genomic instability. NIH 3T3 cells
infected with MuLV (A), v-ras
(B and D), or v-mos (C)
were stained with CREST antibodies directed against kinetochore
proteins and an ALEXA-488-labeled secondary antibody (in
green) and counter-stained with propidium iodide. Images
were obtained with a Bio-Rad confocal microscope using a ×60
objective. Blue and white arrows indicate
micronuclei, and the yellow arrow indicates a binucleated
cell. Most of the nuclei shown in this figure are in interphase,
panel B shows a cell in metaphase (left) with 2 micronuclei and a cell in interphase with a micronucleus
(right). Panel D shows an interphase cell
containing two CREST-positive micronuclei and a CREST-negative
micronucleus.
|
|

View larger version (9K):
[in this window]
[in a new window]
|
Fig. 5.
Ras induces loss of chromosomes, as measured
by the micronucleus assay. Cells infected with MuLV or
v-ras were lysed in the presence of propidium iodide and
sytox and analyzed by flow cytometry. The results presented are the
percentage of micronuclei per nuclei. The number of independenly
transduced populations and the p values resulting from an
unequal variance t test is as follows: MuLV
(n = 10); v-ras (n = 10;
p 7E-6).
|
|

View larger version (11K):
[in this window]
[in a new window]
|
Fig. 6.
Chromosome loss induced by ras
is mediated by MAPK. NIH 3T3 cells were infected with
MuLV, v-ras, or v-mos, and analyzed by
immunocytochemistry. v-ras cells were cultured in the
presence of 75 µM PD98059, 50, 80, or 100 µM U0126, or 1 µM wortmannin. Cells were
fixed, and stained with DAPI. The percentage of micronuclei was
obtained from counting at least 500 nuclei per well using a confocal
microscope and a ×100 objective. The number of cell populations
analyzed and the p values resulting from an unequal variance
t test is as follows: MuLV (n = 14); v-ras (n = 12, compared with
MuLV, p 7.63E-8); v-ras + 75 µM PD98059 (n = 7, compared with
v-ras p 1.58E-6); v-ras + 50 µM U0126 (n = 6; p 2.35E-6); v-ras + 80 µM U0126
(n = 5, p 6.79E-7); v-ras
+100 µM U0126 (n = 3, p 8.67E-7); v-ras + 1 µM wortmannin
(n = 5, p 0.23).
|
|
View this table:
[in this window]
[in a new window]
|
Table I
Growth characteristics of NIH 3T3 cells transduced with MuLV and
v-ras in the presence or absence of chemical inhibitors of the
RAS signal transduction pathways
|
|
Oncogenic ras Induces Micronuclei Formation by the MAPK
Pathway--
Although the generation of micronuclei correlated with
MAPK activation by v-ras and v-mos (which
stimulates only the MAPK pathway), we further tested the involvement of
the MAPK pathway in inducing chromosome loss by treating the
v-ras cells with PD98059 and U0126. As a control, we treated
cells with wortmannin. Treatment of NIH 3T3 cells with MAPK inhibitors
resulted in suppression of micronucleus formation (Fig. 6). Expression
of v-ras resulted in an 8.5-fold increase in micronucleus
formation (Figs. 5 and 6). Treatment of cells that overexpress
v-ras with 75 µM PD98059 resulted in
suppression of micronucleus formation by 60%, whereas treatment of
cells with 50 and 80 µM U0126 resulted in a 65 and 67%
reduction, respectively (Fig. 6). Total inhibition of micronucleus formation could not be accomplished, even at doses that approached undetectable activation of the MAPK pathway such as 100 µM U0126. Treatment of cells with wortmannin did not
result in inhibition of micronucleus formation. At the concentrations
used, PD98059, U0126, or wortmannin did not significantly alter cell
cycle profiles or doubling times (shown for 75 µM) (Table
I), indicating that suppression of micronucleus formation or chromosome
instability was not attributable to changes in growth rates.
Instability Induced by Constitutive Activation of MAPK Involves
Chromosome Missegregation and Binucleation--
Micronucleus formation
reflects damage induced by agents that disrupt the mitotic spindle or
by agents that induce double-strand DNA breaks (45-52). In the former
case, the micronuclei represent whole chromosomes that have not been
incorporated into the daughter nucleus. In the latter case, the
micronuclei are comprised of acentric chromosome fragments. These
alternatives can be distinguished by staining micronuclei with the
anti-centromeric antibody CREST. An example of a micronucleus stained
with CREST is presented in Fig. 4D. Staining with CREST
antibody revealed that at the high levels of activated MAPK induced by
v-ras and v-mos, the percentage of CREST-positive
micronuclei increased dramatically (Fig.
7A). The approximate increase
was 14-fold in cells infected with v-ras and 7-fold in cells
infected with v-mos. CREST-negative micronuclei increased by
approximately 6- and 2-fold in v-ras and
v-mos-infected cells, respectively (Fig. 7B). The
fact that both v-ras and v-mos induce
a disproportionate increase in the number of CREST-positive micronuclei
is suggestive of mitotic instability, since most of the missegregated
chromosomes are lost as whole chromosomes. To confirm that
v-ras was, indeed, inducing mitotic instability, we
estimated the frequency with which v-ras and
v-mos induced the formation of binucleated cells, as an
independent measure of mitotic instability (43, 55). Expression of Ras
and Mos resulted in elevation of the frequency of binucleated cells to 10 and 12%, respectively (Fig. 8).
Binucleation by RAS also seems to be mediated by MAPK, since treatment
of v-ras cells with 75 µM PD98059 suppressed
the formation of binucleated cells by 43% (Fig. 8).

View larger version (12K):
[in this window]
[in a new window]
|
Fig. 7.
Constitutive activation of MAPK results in
loss of whole chromosomes and chromosome fragments. NIH 3T3 cells
were infected with MuLV, v-ras, or
v-mos. Eight days after infection, immunocytochemistry was
performed on infected cells using CREST antibody, which detects
kinetochore proteins. Cells were counterstained with propidium iodide.
Each cell containing a micronucleus was optically sectioned three to
five times on a Kalman/slow mode by confocal microscopy under a ×100
objective. A, percent CREST-positive micronuclei. The number
of analyzed populations and the p values resulting from an
unequal variance t test is as follows: MuLV
(n = 5); v-ras (n = 6, compared with MuLV, p 5.6E-5);
v-mos (n = 5; compared with MuLV,
p 0.03). B, percent CREST-negative
micronuclei. The number of analyzed populations and the p
values resulting from an unequal variance t test is as
follows: MuLV (n = 5); v-ras
(n = 6, compared with MuLV,
p 0.0006); v-mos (n = 5;
compared with MuLV, p 0.11).
|
|

View larger version (10K):
[in this window]
[in a new window]
|
Fig. 8.
Ras and mos induce
binucleation. Cells infected with MuLV,
v-ras cultured in the presence or absence of 75 µM PD98059, and v-mos were stained with CREST
anti-kinetochore antibody and counterstained with propidium iodide. The
percentage of binucleated cells was obtained by confocal microscopy
from the analysis of at least 500 nuclei. Percentages represent the
average of three to four independently infected populations. The number
of analyzed populations and the p values resulting from an
unequal variance t test is as follows: MuLV
(n = 4); v-ras (n = 3, compared with MuLV p 0.02);
v-ras + 75 µM PD98059 (n = 3, compared with v-ras p 0.05),
v-mos (n = 4; p 0.02).
|
|
Constitutive Activation of MAPK Results in Defects in Normal
Mitotic Processes--
The fact that transduction of cells with
v-ras and v-mos resulted in the loss of whole
chromosomes and in the generation of binucleated cells suggested that
constitutive activation of the MAPK pathway resulted in events leading
to defects in the mitotic spindle. Increases in CREST (
) micronuclei
suggested that ras was also inducing clastogenic events. To
determine what are the events that may be leading to chromosome
missegregation, we stained the mitotic spindle with
-tubulin and
centrosomes with
-tubulin. Nuclei were counterstained with DAPI.
Constitutive activation of MAPK resulted in an increase in centrosome
amplification, leading to the formation of multiple mitotic spindles
(31) and in mitotic bridges, which are the result of the formation of
dicentric chromosomes (38). Both of these processes were reduced by
treatment with MAPK inhibitors, but not with an inhibitor of the PI3K
signal transduction pathway (Figs. 9 and
10).

View larger version (32K):
[in this window]
[in a new window]
|
Fig. 9.
MAPK mediates the formation of mitotic
bridges and centrosome amplification. Cells were infected with
MuLV (panels A and B), or with
v-ras (panels C and D), and fixed as
described under "Experimental Procedures." Centrosomes were stained
with anti- -tubulin and Alexa-488 (in green). The mitotic
spindle was stained with anti- -tubulin and Alexa-546 (in
red). Nuclei were stained with DAPI. A, normal
telophase in a vector control cell (MuLV), stained with
DAPI; B, normal anaphase from MuLV-infected cells
showing one centrosome at each spindle pole. C, defective
telophase in a v-ras-infected cell, showing a chromosome
bridge between the two daughter cells (indicated by the
arrow). D, multipolar anaphase (indicated by the
arrow); notice the abnormal mitotic spindle which forms from
each of the centrosomes.
|
|

View larger version (15K):
[in this window]
[in a new window]
|
Fig. 10.
Activated MAPK induces mitotic bridges.
Cells were infected with MuLV and v-ras.
v-ras cells were cultured in the presence or absence of the
MAPK inhibitor U0126, or the PI3K inhibitor wortmannin as described
under "Experimental Procedures." The results represent analysis of
at least 100 mitotic cells per experiment. Black bars
represent the percentage of mitotic bridges, whereas gray
bars represent mitotic cells with amplified centrosomes. The
number of independent experiments and the p values resulting
from an unequal variance t test are as follows:
MuLV (n = 2); v-ras
(n = 2, compared with MuLV: bridges p 0.006; centrosome amplification p 0.005); v-ras + 50 µM U0126 (n = 2; compared with
v-ras: bridges: p 0.018; centrosome
amplification: p 0.012); v-ras + 80 µM U0126 (n = 2; compared with
v-ras: bridges p 0.02; centrosome
amplification p 0.0018); v-ras + 1 µM wortmannin (n = 2, compared with
v-ras: bridges p 0.62; centrosome
amplification p 0.11).
|
|
 |
DISCUSSION |
The Ras signal transduction pathways control normal cellular
functions such as growth (12, 13), differentiation (13, 14), and cell
morphology (15-18, 28). The Ras signal transduction pathways can also
mediate responses to stress such as hypoxia (19), as well as contribute
to the induction of apoptosis in hematopoietic cells in response to FAS
(24, 25) or TNF (26).
Mutations within the cellular Ras genes render Ras and its
signal transduction pathways constitutively active and lead to potentially deleterious cellular consequences including cellular transformation and uncontrolled growth rates (4, 12, 13, 15, 17, 18,
32). Overexpression of constitutively active Ras also
induces programmed cell death (reviewed in Ref. 56) in primary mouse
embryo fibroblasts (43), NIH 3T3 cells (57), in COS-7 cells expressing
BAD (58), and in Jurkat human lymphoblastoid T-cells (59).
Overproduction of oncogene products related to proteins within the Ras
signal transduction pathway, such as Mos, induce apoptosis in Swiss 3T3
(55) and p53+/+ and p53
/
mouse embryonic
fibroblasts (43).
Expression of the Ras oncogene also leads to genomic
instability. In NIH 3T3 cells, selective induction of the human EJ
Ha-Ras oncogene expression leads to several phenotypes
associated with genomic instability, such as gene amplification (34,
35), generation of aberrant chromosomes (33, 36) within a single cell
cycle (33), and chromosome missegregation (37, 38). Induction of
genomic instability by oncogenic Ras and oncogenes within
the Ras signal transduction pathway seems to be a general phenomenom,
since it occurs in cell lines such as rat mammary carcinoma cells (39),
rat prostatic tumor cells (40), human colon carcinoma cells (39), Swiss
3T3 fibroblasts, and p53
/
mouse primary fibroblasts
(43, 55).
Since the Ras signal transduction pathway is not strictly linear, but
is complex with multiple intersections and bifurcations (9-11), we
asked whether activation of a single branch, namely the MAPK pathway,
was sufficient to induce chromosome instability. We have chosen to
dissect this pathway by using the MAPKK inhibitors PD98059 and U0126
and by overexpressing the v-mos oncogene, which leads to
direct activation of the MAPK pathway (60, 61). As a control, we
inhibited the Ras/PI3K signal transduction pathway with the chemical
inhibitor wortmannin. We studied ras induction of chromosome
instability at the population level, due to the inherent instability of
p53 mutant NIH 3T3 cells (29-31, 33), and to reduce clonal variability
in studying chromosome instability.
Our results indicate that selective expression of oncogenic
ras results in whole chromosome and chromosome fragment
loss, as measured by the micronucleus assay. Micronuclei are a
reflection of genetic damage and subsequent loss of genetic material.
Micronuclei can be generated by the action of clastogens (agents that
induce acentric chromosomes by producing chromosome breaks) or aneugens (agents that induce loss of whole chromosomes by interfering with the
mitotic spindle) (42, 45-52, 62).
There is little available evidence to indicate which of the
Ras-mediated pathways most actively promotes genomic instability. The
MAPK pathway has been implicated since mos induces genomic instability via MAPK, and since there are no known bifurcations of the
MAPK pathway downstream of Mos (43, 55). To directly test whether
ras induces genomic instability via MAPK, we treated ras-overexpressing cells with the specific MAPKK inhibitors
PD98059 and U0126. We also infected cells with the mos
oncogene. We have shown that micronucleus formation induced by
ras is mediated, in large part, by the MAPK pathway, since
the MAPKK inhibitors suppressed formation of ras-induced
micronuclei, and direct induction of MAPK activation by mos
also resulted in micronuclei formation. In contrast, total inhibition
of the PI3K signal transduction pathway did not inhibit micronucleus
formation. Formation of micronuclei cannot be attributable to higher
growth rates, since the ras cells showed a similar
replication index that vector control cells, and slowed down during
mitosis, as has been described for mos-transformed cells
(63). To ascertain the predominant mechanism by which ras
and mos induce micronuclei, we stained micronuclei with the anti-kinetochore antibody CREST, which recognizes the centromeric proteins CENP-A, -B, and -C (64). Increases in CREST-negative micronuclei have been associated with DNA-damaging agents such as
-irradiation, and correlates directly with loss of centromeric
-satellite DNA sequences, whereas increases in CREST-positive micronuclei results from agents that disrupt the mitotic spindle (45,
62). At high levels of activated MAPK, ras and
mos disproportionately increased the frequency of
CREST-positive micronuclei, suggesting that most of the micronuclei
induced by ras and mos are missegregated whole
chromosomes. The fact that ras and mos also
increased the frequency of CREST-negative micronuclei is consistent
with previous observations that ras induces chromosome
breaks leading to increases in the frequency of acentric fragments
(33), and other chromosome anomalies (33, 36-41), and to gene
amplification (34, 35) resulting from the induction of multiple
bridge-break fusion cycles (reviewed in Ref. 65). The fact that both
CREST-positive and -negative micronuclei are generated suggests that at
least two mechanisms may be operative in the MAPK-mediated induction of genomic instability. One is the generation of acentric fragments, possibly as a result of endonucleolytic activity (66). The second is
the improper segregation of whole chromosomes that contain the
necessary centromeric machinery to be segregated properly. To confirm
that ras and mos induced mitotic instability, we
quantitated the increase in binucleated cells, which serves as an
independent measure of mitotic instability due to abnormalities of the
mitotic spindle (43, 55). Expression of ras and
mos increased the frequency of binucleated cells, which was
suppressed by treatment of the cells with the MAPKK inhibitor PD98059.
Formation of micronuclei correlates with an increased number of mitotic
defects induced by high activation of the MAPK pathway. The predominant
defect induced by v-ras is the formation of mitotic bridges,
which are the result of the acquisition of one or more centromeres due
to breakage and fusions of chromosomes and the consequent stretching of
chromosomes when the daughter cells separate during mitosis (38).
Another defect induced by v-ras is the induction of
centrosome amplification, which results in the formation of multiple
mitotic spindles and the consequent missegregation of chromosomes. Both of these phenotypes are strongly inhibited by MAPK inhibitors.
The observation that mitotic instability induced by oncogenic
ras involves the MAPK pathway makes it possible to dissect
the mechanism(s) that produce this instability in mammalian cells. The
initial evidence implicating MAPK in the regulation of mitosis came
from studies of Xenopus meiosis where MAPK promotes oocyte maturation (67-73). In contrast, during embryogenesis, MAPK plays a
negative regulatory role, since activation of MAPK by Mos or injection
of active MAPK into Xenopus embryos leads to mitotic arrest
(74, 75). MAPK also plays a role in the Xenopus spindle assembly checkpoint, an evolutionarily conserved mechanism that monitors defects in the mitotic spindle or improper alignment of
chromosomes during mitosis (reviewed in Refs. 76 and 77). MAPK
activation establishes a mitotic spindle checkpoint; active MAPK
increases dramatically in nocodazole-treated Xenopus egg extracts, and the cells could be released from the arrest by addition of the MAPK phosphatase MKP-1 (78). In somatic cells, evidence involving MAPK in the spindle assembly checkpoint stems from recent observations that MAPK is activated in response to nocodazole and that
the arrest is overridden by the MAPK phosphatase XCL100 (79).
Similarly, immunodepletion of MAPK in cycling Xenopus extracts or treatment with PD98059 causes precocious termination of
mitosis and interferes with production of normal mitotic microtubules (80).
The relationship between MAPK activation and its involvement in mitosis
in mammalian cells is less clear. Microinjection of fibroblasts with
antibodies against c-src blocks entry into mitosis, suggesting a link between upstream components of signal transduction pathways and mitosis (81). Recent reports suggest a possible role for
MAPK in regulation of mammalian mitosis. Active MAPK localizes to the
kinetochores during mitosis and phosphorylates proteins such as CENP-E,
a motor protein involved in chromosome movement (54). MAPK also
phosphorylates proteins containing the 3F3/2 phosphoantigen (82), which
are involved in the mammalian mitotic checkpoint (83). The
dephosphorylation of this antigen is required for progression to
anaphase (84). Interestingly, one of the proteins sharing the 3F3/2
antigens is topoisomerase II
, an enzyme that generates regulated
strand breaks to ensure proper condensation of chromosomes during
mitosis (85). Topoisomerase II
has been postulated to be the enzyme
that may be involved in the chromosomal breaks and recombination
induced by the ras oncogene (41), is modulated by the
ras oncogene (86), and is activated by the MAPK pathway
(87). Whether topoisomerase II is the enzyme which actually leads to
RAS-induced chromosome breaks that produce the breakage-fusion cycle
leading to the formation of CREST-negative micronuclei (acentric
chromosomes), dicentric chromosomes, and mitotic bridges remains to be elucidated.
 |
ACKNOWLEDGEMENTS |
We thank Drs. Yolanda Sanchez, Jeffrey
Knauf, and Anthony Capobianco for helpful discussions. We also thank
Dr. George Babcock and Jim Cornelius for assistance in the flow cytometry.
 |
FOOTNOTES |
*
This work was supported by National Institutes of Health
Grant CA65769.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
Supported in part by NIEHS National Institutes of Health Training
Grant ES07250. Current address: Div. of Cancer Genetics, The Ohio State
University, Rm. 690, Medical Research Facility, 420 W. 12th Ave.,
Columbus, OH 43210. Tel.: 614-292-2459; Fax: 614-688-4245.
¶
To whom correspondence should be addressed. Tel.:
513-558-5685; Fax: 513-558-4454.
 |
ABBREVIATIONS |
The abbreviations used are:
MAP, mitogen-activated protein;
MAPK, mitogen-activated protein kinase;
PI, propidium iodide;
PI3K, phosphatidylinositol 3-kinase;
PBS, phosphate-buffered saline;
Pipes, 1,4-piperazinediethanesulfonic
acid;
CHAPS, 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonic acid;
MOPS, 4-morpholinepropanesulfonic acid;
DAPI, 4',6-diamidino-2-phenylindole.
 |
REFERENCES |
| 1.
|
Boguski, M.,
and McCormick, F.
(1993)
Nature
366,
643-653[CrossRef][Medline]
[Order article via Infotrieve]
|
| 2.
|
Bokoch, G.,
and Der, C.
(1993)
FASEB J.
7,
750-759[Abstract]
|
| 3.
|
Gibbs, J.,
Sigal, I.,
Poe, M.,
and Scolnick, E.
(1984)
Proc. Natl. Acad. Sci. U. S. A.
81,
5704-5708[Abstract/Free Full Text]
|
| 4.
|
Shih, C.,
and Weinberg, R. A.
(1982)
Cell
29,
161-169[CrossRef][Medline]
[Order article via Infotrieve]
|
| 5.
|
Johnson, G.,
and Vaillancourt, R.
(1994)
Curr. Opin. Cell Biol.
6,
230-238[CrossRef][Medline]
[Order article via Infotrieve]
|
| 6.
|
Lewis, T. S.,
Shapiro, P. S.,
and Ahn, N. A.
(1998)
Adv. Cancer Res.
65,
48-139
|
| 7.
|
Marshall, C. J.
(1995)
Cell
80,
179-185[CrossRef][Medline]
[Order article via Infotrieve]
|
| 8.
|
Bruder, J.,
Heidicker, G.,
and Rapp, U.
(1992)
Genes Dev.
6,
545-556[Abstract/Free Full Text]
|
| 9.
|
Avruch, J.,
Zhang, X.,
and Kyriakis, J. M.
(1994)
Trends Biochem. Sci.
19,
279-283[CrossRef][Medline]
[Order article via Infotrieve]
|
| 10.
|
Khosravi-Far, R.,
Campbell, S.,
Rossman, K. L.,
and Der, C. J.
(1998)
Adv. Cancer Res.
65,
56-107
|
| 11.
|
Frost, J. A.,
Steen, H.,
Shapiro, P.,
Lewis, T.,
Ahn, N.,
Shaw, P. E.,
and Cobb, M. H.
(1997)
EMBO J.
16,
6426-6438[CrossRef][Medline]
[Order article via Infotrieve]
|
| 12.
|
Liu, J. J.,
Chao, J. R.,
Jiang, M. J.,
Ng, S. Y.,
Yan, J. J. Y.,
and Yang-Yen, H. F.
(1995)
Mol. Cell. Biol.
15,
3654-3663[Abstract]
|
| 13.
|
Cowley, S.,
Paterson, H.,
Kemp, P.,
and Marshall, C. J.
(1994)
Cell
77,
841-852[CrossRef][Medline]
[Order article via Infotrieve]
|
| 14.
|
Lange-Carter, C. A.,
and Johnson, G. L.
(1994)
Science
265,
1458-1461[Abstract/Free Full Text]
|
| 15.
|
Khosravi-Far, R.,
Solski, P. A.,
Clark, G. J.,
Kinch, M. S.,
and Der, C. J.
(1995)
Mol. Cell. Biol.
15,
6443-6453[Abstract]
|
| 16.
|
Qiu, R.-G.,
Abo, A.,
McCormick, F.,
and Symons, M.
(1997)
Mol. Cell. Biol.
17,
3449-3458[Abstract]
|
| 17.
|
Joneson, T.,
White, M. A.,
Wigler, M. H.,
and Bar-Sagi, D.
(1996)
Science
271,
810-812[Abstract]
|
| 18.
|
Clark, G. J.,
Westwick, J. K.,
and Der, C. J.
(1997)
J. Biol. Chem.
272,
1677-1681[Abstract/Free Full Text]
|
| 19.
|
Koong, A. C.,
Chen, E. Y.,
Mivechi, N. F.,
Denko, N. C.,
Stambrook, P. J.,
and Giaccia, A. J.
(1994)
Cancer Res.
54,
5273-5279[Abstract/Free Full Text]
|
| 20.
|
Derijard, B.,
Hibi, M.,
Wu, I. H.,
Barret, T.,
Su, B.,
Deng, T.,
Karin, M.,
and Davis, R. J.
(1994)
Cell
76,
1025-1037[CrossRef][Medline]
[Order article via Infotrieve]
|
| 21.
|
Minden, A.,
Lin, A.,
McMahon, M.,
Lange-Carter, C.,
Derjard, B.,
Davis, R. J.,
Johnson, G. L.,
and Karin, M.
(1994)
Science
266,
1719-1723[Abstract/Free Full Text]
|
| 22.
|
Minden, A.,
and Karin, M.
(1997)
Biochim. Biophys. Acta
1333,
F86-F104
|
| 23.
|
Coso, O. A.,
Chiariello, M., Yu, J. C.,
Teramoto, H.,
Crespo, P.,
Xu, N.,
Miki, T.,
and Gutkind, J. S.
(1995)
Cell
81,
1137-1146[CrossRef][Medline]
[Order article via Infotrieve]
|
| 24.
|
Gulbins, G.,
Bissonnette, R.,
Mahboubi, A.,
Martin, S.,
Nishioka, W.,
Brunner, T.,
Baier, G.,
Baier-Bitterlich, G.,
Byrd, C.,
Lang, F.,
Kolesnick, R.,
Altman, A.,
and Green, D.
(1995)
Immunity
2,
341-351[CrossRef][Medline]
[Order article via Infotrieve]
|
| 25.
|
Goillot, E.,
Raingeaud, J.,
Ranger, A.,
Tepper, R. I.,
Davis, R. J.,
Harlow, E.,
and Sanchez, I.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
3302-3307[Abstract/Free Full Text]
|
| 26.
|
Trent, J. C., II,
Conkey, D. J.,
Moughlin, S. M.,
Harbison, M. T.,
Fernandez, A.,
and Ananthaswamy, H. N.
(1996)
EMBO J.
15,
4497-4505[Medline]
[Order article via Infotrieve]
|
| 27.
|
Hu, Q.,
Klippel, A.,
Muslin, A. J.,
Fantl, W. J.,
and Williams, L. T.
(1995)
Science
268,
100-102[Abstract/Free Full Text]
|
| 28.
|
Rodriguez-Viciana, P.,
Warne, P. H.,
Khwaja, A.,
Marte, B. M.,
Pappin, D.,
Das, P.,
Waterfield, M. D.,
Ridley, A.,
and Downard, J.
(1997)
Cell
89,
457-467[CrossRef][Medline]
[Order article via Infotrieve]
|
| 29.
|
Livingstone, L. R.,
White, A.,
Sprouse, J.,
Livanos, E.,
Jacks, T.,
and Tlsty, T. D.
(1992)
Cell
70,
923-935[CrossRef][Medline]
[Order article via Infotrieve]
|
| 30.
|
Yin, Y.,
Tainsky, M. A.,
Bischoff, F. Z.,
Strong, L. C.,
and Wahl, G. M.
(1992)
Cell
70,
937-948[CrossRef][Medline]
[Order article via Infotrieve]
|
| 31.
|
Fukasawa, K.,
Choi, T.,
Kuriyama, R.,
Rulong, S.,
and Vande Woude, G. F.
(1996)
Science
271,
1744-1747[Abstract]
|
| 32.
|
Liu, H. S.,
Scrable, H.,
Villaret, D. B.,
Lieberman, M. A.,
and Stambrook, P. J.
(1992)
Cancer Res.
52,
983-989[Abstract/Free Full Text]
|
| 33.
|
Denko, N.,
Giaccia, A.,
Stringer, J.,
and Stambrook, P.
(1994)
Proc. Natl. Acad. Sci. U. S. A.
91,
5124-5128[Abstract/Free Full Text]
|
| 34.
|
Wani, M. A.,
Xu, X.,
and Stambrook, P. J.
(1994)
Cancer Res.
54,
2504-2508[Abstract/Free Full Text]
|
| 35.
|
Wani, M. A.,
Denko, N. C.,
and Stambrook, P. J.
(1997)
Somat. Cell Mol. Genet.
23,
123-133[Medline]
[Order article via Infotrieve]
|
| 36.
|
van den Berg, S.,
Kaina, B.,
Rahmsdorf, H. J.,
Ponta, H.,
and Herlich, P.
(1991)
Mol. Carcinogen.
4,
460-466[Medline]
[Order article via Infotrieve]
|
| 37.
|
Hagag, N.,
Diamond, L.,
Palermo, R.,
and Lyubsky, S.
(1990)
Oncogene
5,
1481-1489[Medline]
[Order article via Infotrieve]
|
| 38.
|
Denko, N.,
Stringer, J.,
Wani, M.,
and Stambrook, P. J.
(1995)
Somatic Cell Mol. Genet.
21,
241-253[CrossRef][Medline]
[Order article via Infotrieve]
|
| 39.
|
Ichikawa, T.,
Kyprianou, N.,
and Isaacs, J. T.
(1990)
Cancer Res.
50,
6349-6357[Abstract/Free Full Text]
|
| 40.
|
Ichikawa, T.,
Schalken, J. A.,
Ichikawa, Y.,
Steinberg, G. D.,
and Isaacs, J. T.
(1991)
Prostate
18,
163-172[Medline]
[Order article via Infotrieve]
|
| 41.
|
de Vries, J. E.,
Kornips, F. H. A.,
Marx, P.,
Bosman, F. T.,
Geraedts, J. P. M.,
and Kate, J.
(1993)
Cancer Genet. Cytogenet.
65,
35-43[CrossRef][Medline]
[Order article via Infotrieve]
|
| 42.
|
Nusse, M.,
Beisker, W.,
Kramer, J.,
Miller, B. M.,
Schreiber, G. A.,
Viaggi, S.,
Weller, E. M.,
and Wessels, J.
(1994)
Methods Cell Biol.
42,
149-157
|
| 43.
|
Fukasawa, K.,
and Vande Woude, G. F.
(1997)
Mol. Cell. Biol.
17,
506-518[Abstract]
|
| 44.
|
Lane, D.,
and Harlow, E.
(1988)
Antibodies: A Laboratory Manual
, Cold Spring Harbor Laboratory Press, Cold Spring, NY
|
| 45.
|
Schiriever-Schwemmer, G.,
and Adler, I-D.
(1994)
Mutagenesis
9,
333-340[Abstract/Free Full Text]
|
| 46.
|
Hennig, U. G. G.,
Rudd, N. L.,
and Hoar, D. I.
(1988)
Mutat. Res.
203,
405-414[Medline]
[Order article via Infotrieve]
|
| 47.
|
Thompson, E. J.,
and Perry, P. E.
(1988)
Mutagenesis
3,
415-418[Abstract/Free Full Text]
|
| 48.
|
Miller, B. M.,
and Adler, I.-D.
(1990)
Mutagenesis
5,
411-415[Abstract/Free Full Text]
|
| 49.
|
Degrassi, F.,
and Tanzarella, C.
(1988)
Mutat. Res.
203,
339-345[Medline]
[Order article via Infotrieve]
|
| 50.
|
Gudi, R.,
Sandhu, S. S.,
and Athwal, R. S.
(1990)
Mutat. Res.
234,
263-268[Medline]
[Order article via Infotrieve]
|
| 51.
|
Miller, B. M.,
Zitzelsberger, H. F.,
Weier, H.-,
Ul, G.,
and Adler, I.-D.
(1991)
Mutagenesis
6,
297-302[Abstract/Free Full Text]
|
| 52.
|
Fenech, M.,
and Morley, A. A.
(1989)
Mutagenesis
4,
98-104[Abstract/Free Full Text]
|
| 53.
|
Darzynkiewicz, Z.,
and Juan, G.
(1997)
Current Protocols in Cytometry
, Vol. 1
, pp. 7.7.1-7.7.9, John Wiley & Sons, New York
|
| 54.
|
Zecevic, M.,
Catling, A. D.,
Eblen, S. T.,
Renzi, L.,
Hittle, J. C.,
Yen, T. J.,
Gorbsky, G. J.,
and Weber, M. J.
(1998)
J. Cell Biol.
142,
1547-1558[Abstract/Free Full Text]
|
| 55.
|
Fukasawa, K.,
and Vande Woude, G. F.
(1995)
Proc. Natl. Acad. Sci. U. S. A.
92,
3430-3434[Abstract/Free Full Text]
|
| 56.
|
Downard, J.
(1998)
Curr. Opin. Genet. Dev.
8,
49-54[CrossRef][Medline]
[Order article via Infotrieve]
|
| 57.
|
Liu, H. S.,
Chen, C. H.,
and Chou, Y. I.
(1998)
Br. J. Cancer
77,
1777-1786[Medline]
[Order article via Infotrieve]
|
| 58.
|
Basu, S.,
Bayoumy, S.,
Zhang, Y.,
Lozano, J.,
and Kolesnick, R.
(1998)
J. Biol. Chem.
273,
30419-30426[Abstract/Free Full Text]
|
| 59.
|
Chen, C. Y.,
Liou, J.,
Forman, L. W.,
and Faller, D.
(1998)
J. Biol. Chem.
273,
16700-16709[Abstract/Free Full Text]
|
| 60.
|
Posada, J.,
Yew, N.,
Ahn, N. G.,
Vande Woude, G. F.,
and Cooper, J. A.
(1993)
Mol. Cell. Biol.
13,
2546-2553[Abstract/Free Full Text]
|
| 61.
|
Nebreda, A. R.,
Hill, C.,
Gomez, N.,
Cohen, P.,
and Hunt, T.
(1993)
FEBS Lett.
333,
183-187[CrossRef][Medline]
[Order article via Infotrieve]
|
| 62.
|
Miller, B. M.,
and Nusse, M.
(1993)
Mutagenesis
8,
35-41[Abstract/Free Full Text]
|
| 63.
|
Okasaki, K.,
Nishizawa, M.,
Furuno, N.,
Yasuda, H.,
and Sagata, N.
(1992)
EMBO J.
11,
2447-2456[Medline]
[Order article via Infotrieve]
|
| 64.
|
Larin, Z.,
Fricker, M. D.,
and Tyler-Smyth, C.
(1994)
Hum. Mol. Genet.
3,
689-695[Abstract/Free Full Text]
|
| 65.
|
Windle, B. E.,
and Wahl, G. M.
(1992)
Mutat. Res.
276,
199-224[CrossRef][Medline]
[Order article via Infotrieve]
|
| 66.
|
Russo, C. A.,
Weber, T. K.,
Volpe, C. M.,
Stoler, D. L.,
Petrelli, N. J.,
Rodriguez-Bigas, M.,
Burhans, W. C.,
and Anderson, G. R.
(1995)
Cancer Res.
55,
1122-1128[Abstract/Free Full Text]
|
| 67.
|
Ferrell, J. E.,
Wu, M.,
Gerhart, J. C.,
and Martin, G. S.
(1991)
Mol. Cell. Biol.
11,
1965-1971[Abstract/Free Full Text]
|
| 68.
|
Jessus, C.,
Rime, H.,
Haccard, O.,
Van Lint, J.,
Goris, J.,
Merlevede, W.,
and Orzon, R.
(1991)
Development
111,
813-820[Abstract]
|
| 69.
|
Posada, J.,
Sanghera, J.,
Pelech, S.,
Aebersold, R.,
and Cooper, J. A.
(1991)
Mol. Cell. Biol.
11,
2517-2528[Abstract/Free Full Text]
|
| 70.
|
Kosako, H.,
Gotoh, Y.,
and Nishida, E.
(1994)
EMBO J.
13,
2131-2138[Medline]
[Order article via Infotrieve]
|
| 71.
|
Gotoh, Y.,
Masuyama, N.,
Dell, K.,
Shirakabe, K.,
and Nishida, E.
(1995)
J. Biol. Chem.
270,
25898-25904[Abstract/Free Full Text]
|
| 72.
|
Haccard, O.,
Lewellyn, A.,
Hartley, R. S.,
Erikson, E.,
and Maller, J. L.
(1995)
Dev. Biol.
168,
677-682[CrossRef][Medline]
[Order article via Infotrieve]
|
| 73.
|
Sagata, N.
(1997)
Bioessays
19,
13-21[CrossRef][Medline]
[Order article via Infotrieve]
|
| 74.
| |